. 2022 May 27;11(7):e220143. doi: 10.1530/EC-22-0143
This work is licensed under a Table 2.
Glucocorticoid therapy in 62 patients with 21-hydroxylase deficiency treated at the Department of Endocrinology, Rigshospitalet, Denmark. The classic form includes both the simple virilizing and the salt-wasting form.
| Glucocorticoid treatment | Total (n = 62) | Classic (n = 34) | Non-classic (n = 28) | P-value |
|---|---|---|---|---|
| Glucocorticoid treatment years median (IQR) | 24 (16–46) | 41 (24–51) | 16 (8–23) | <0.001 |
| Hydrocortisone treatment | ||||
| n (%) | 58 (94) | 31 (91) | 27 (96) | 0.40 |
| Median dose, mg/day (range) | 20 (5–50) | 20 (5–50) | 15 (5–25) | 0.002 |
| Dexamethasone treatment | ||||
| n (%) | 24 (39) | 18 (53) | 6 (21) | 0.011 |
| Median dose (range) (mg/day) | 0.1 (0.05–0.5) | 0.1 (0.05–0.5) | 0.1 (0.05–0.2) | 0.23 |
| Prednisolone treatment | ||||
| n (%) | 3 (5) | 3 (9) | – | |
| Median dose (range) (mg/day) | 7.5 (2.0–7.5) | 7.5 (2.07.5) | – | |
| Combination of glucocorticoid preparations n (%) | 23 (37) | 18 (53) | 5 (18) | 0.004 |
| Total glucocorticoid dose (mg HC) ± s.d. | 20 ± 9 | 25 ± 9 | 15 ± 7 | <0.001 |
| Total glucocorticoid dose (mg HC/m2/day) (IQR) | 11.7 (8.0–14.7) | 13.4 (10.6–16.6) | 10.7 (6.2–12.4) | 0.002 |
HC, hydrocortisone; IQR, interquartile range.